Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-20

I wouldn't read too much into the GAG response since it is in addition to ERT's. PAR would need to include kids not taking ERT's to evaluate DM, not sure why they didn't. GAG levels are also highly variable. Definitely can only see it being used as an adjuvant therapy. I don't see PAR commanding 50k per treatment cycle as others have indicated, but around 5k max. Unlikely to make the money back that we invested in R&D, so best to shelve the MPS project until someone pays for a license to use the data package. Who knows, maybe MPS is part of the cost cutting measures PAR are taking.